There are currently 59 active clinical trials seeking participants for Rheumatoid Arthritis research studies. The states with the highest number of trials for Autism participants are Florida, California, Texas and Pennsylvania.
Atherosclerosis in Rheumatoid Arthritis and Lupus: Restoring Cholesterol Balance
NCT01180361
Recruiting
Hypothesis: SLE and RA increase risk of myocardial infarction (MI, heart attack). Immune reactants in the circulation of SLE patients downregulate cholesterol efflux proteins 27-hydroxylase and ABCA1 and upregulate scavenger receptor CD36, thus encouraging cholesterol accumulation. Adenosine A2A receptor agonist or statin treatment of cells exposed to SLE plasma (or immune complexes or cytokine-enriched plasma fractions from SLE patients) may ameliorate inflammatory properties of their plasma, l... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/24/2024
Locations: NYU Langone Hospital - Long Island, Mineola, New York
Conditions: Rheumatoid Arthritis
Register for Updates
Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders
NCT05718583
Recruiting
This study is a pilot, proof of concept study to determine the effects of administering an oral short-chain fatty acid (SCFA) supplement to Rheumatoid Arthritis (RA) patients with inadequate response to methotrexate (MTX). The study will include up to 35 participants to obtain a sample size of at least 25 participants taking the oral supplement. The researchers hypothesize that oral SCFA will change the participants' gut microbiome and regulatory immune responses. Clinical data to assess for adv... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: NYU Langone Health Orthopedic Center, New York, New York
Conditions: Rheumatoid Arthritis
Register for Updates
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03414502
Recruiting
This is a 16-week, open-label study to identify factors that help predict clinical responses to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is determined to be necessary will be considered... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
01/02/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Rheumatoid Arthritis
Register for Updates
Rheumatology Patient Registry and Biorepository
NCT04402086
Recruiting
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
12/21/2023
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Register for Updates
PatientSpot Formerly Known as ArthritisPower
NCT03840928
Recruiting
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psor... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
12/12/2023
Locations: Global Healthy Living Foundation, Upper Nyack, New York
Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Register for Updates
Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System
NCT03626038
Recruiting
This study is a multicenter, prospective, non-randomized, non-controlled post-market clinical follow-up study. The primary objective of this study is to confirm the safety and performance of the A.L.P.S. Proximal Humerus Plating System applied in proximal humerus fracture treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Foundation for Orthopaedic Research & Education, Tampa, Florida +1 locations
Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture
Register for Updates
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
NCT05363891
Recruiting
Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: Accurate Clinical Research Inc, Lake Charles, Louisiana +2 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT03297775
Recruiting
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the devel... Read More
Gender:
All
Ages:
Between 45 years and 90 years
Trial Updated:
11/28/2023
Locations: University of Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Rheumatoid Arthritis, Interstitial Lung Disease
Register for Updates
Insignia™ Hip Stem Outcomes Study
NCT05144191
Recruiting
The objective of this study is to evaluate the safety and effectiveness of the Insignia™ Hip Stem for global market access and post-market clinical follow-up up to 10 years postoperative.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: Reno Orthopedic Center Foundation, Reno, Nevada +1 locations
Conditions: Hip Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Post-traumatic Osteoarthritis, Femoral Neck Fractures, Trochanteric Fractures, Surgery
Register for Updates
Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route
NCT06126042
Recruiting
This is a randomised, double-blind, single dose, parallel groups study to compare the PK, immunogenicity, and safety of 3 abatacept products (DRL_AB, RP and RMP) in male NHV.
Gender:
Male
Ages:
Between 18 years and 50 years
Trial Updated:
11/08/2023
Locations: ICON, plc., Lenexa, Kansas +2 locations
Conditions: Rheumatoid Arthritis
Register for Updates
COVID-19 VaccinE Response in Rheumatology Patients
NCT05080218
Recruiting
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prio... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Register for Updates
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
NCT05246280
Recruiting
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Attune Health Research, Beverly Hills, California +21 locations
Conditions: Rheumatoid Arthritis
Register for Updates